Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/muta...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Wang, Aoli, Yan, Xiao-E, Wu, Hong, Wang, Wenchao, Hu, Chen, Chen, Cheng, Zhao, Zheng, Zhao, Peng, Li, Xixiang, Wang, Li, Wang, Beilei, Ye, Zi, Wang, Jinhua, Wang, Chu, Zhang, Wei, Gray, Nathanael S., Weisberg, Ellen L., Chen, Liang, Liu, Jing, Yun, Cai-Hong, Liu, Qingsong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342513/
https://ncbi.nlm.nih.gov/pubmed/27626175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11951
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak